<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354768</url>
  </required_header>
  <id_info>
    <org_study_id>5971</org_study_id>
    <nct_id>NCT02354768</nct_id>
  </id_info>
  <brief_title>Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study</brief_title>
  <acronym>ILEHOS</acronym>
  <official_title>Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dehydration is a major problem of high output stoma with a 17% rate of readmission at 30
      days. Dehydratations are resulting of significant electrolyte loss: sodium, potassium and
      renal failure. Nowadays, there are no recommendations nor national nor international for high
      output ileostomy treatment. Apart from the anti-diarrhea treatments used in current practice,
      somatostatin analogs have proven efficacy in the literature. Theses analogs permit to
      decrease significantly gastrointestinal secretions. Several teams use these analogs in order
      to decrease the flow of highly productive ileostomy.

      The aim of the study is to evaluate the efficacy first line treatment with lanreotide
      associated with current anti-diarrheal treatment for patients with high output ileostomy (or
      greater throughput 1.5l / 24h) with or without associated dehydration
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 22, 2015</start_date>
  <completion_date type="Actual">January 26, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ileostomy bags used per day</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of ileostomy bags used per day</measure>
    <time_frame>from Day 0 to Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood urea and creatinine rates</measure>
    <time_frame>every 2 days until Day6 (Day 0, Day 2, Day 4, Day 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>duration of hospital stay, an expected average of 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>Day 0, Day 1 Day 2, Day3, Day 4, Day 5, Day 6, 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>High Output Stoma</condition>
  <arm_group>
    <arm_group_label>lanreotide and anti-diarrheal treatments</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lanreotide: 1 single injection at day 0 (lanreotide 120 mg)
Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)
Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)
hydration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current anti-diarrheal treatments alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)
Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)
Hydration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)</intervention_name>
    <arm_group_label>lanreotide and anti-diarrheal treatments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone</intervention_name>
    <arm_group_label>Current anti-diarrheal treatments alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Legal at the time of signing the agreement

          -  Subject affiliated to the french social protection

          -  Ileostomy has achieved since 10 days minimum at day 0 (D0: start of study treatment)

          -  Ileostomy output &gt; 1.5 liters / 24h for at least 24 hours at day 0

          -  accept to use an effective method of contraception during the study: (during the 6
             months following injection of lanreotide for the experimental group and for the
             control group: 4 days after the last dose of chlorhydrate of loperamide

          -  People able to understand the objectives, modalities and risks related to the study
             and give written informed consent

        Exclusion Criteria:

          -  people with guardianship or with judicial protection

          -  simultaneous participation in another biomedical research protocol involving a drug or
             topic exclusion period

          -  pregnancy or breastfeeding

          -  administration of lanreotide or related peptide between surgery and D0

          -  hypersensitivities to lanreotide or related peptides and / or diosmectite and / or
             loperamide and / or one of their excipients

          -  acute hemorrhagic colitis

          -  bloody diarrhea and / or high fever

          -  Clostridium Difficile Infection at the inclusion

          -  uncontrolled diabetis defined by HbA1c&gt; 7% at D0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit ROMAIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz - Service de Chirurgie Digestive</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Civils de Colmar - Service de Chirurgie Digestive</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Bocage - CHU Dijon- Service de Chirurgie Digestive</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Emile MULLER - Service de Chirurgie Digestive</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré Service de chirurgie générale, digestive et endocrinienne</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre-Service de Chirurgie Digestive</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
    <mesh_term>Loperamide</mesh_term>
    <mesh_term>Antidiarrheals</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

